<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pak J Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">Pak J Med Sci</journal-id><journal-title-group><journal-title>Pakistan Journal of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1682-024X</issn><issn pub-type="epub">1681-715X</issn><publisher><publisher-name>Professional Medical Publications</publisher-name><publisher-loc>Pakistan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28523042</article-id><article-id pub-id-type="pmc">5432709</article-id><article-id pub-id-type="publisher-id">PJMS-33-383</article-id><article-id pub-id-type="doi">10.12669/pjms.332.11925</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of conjugated linoleic acid supplementation on quality of life in rectal cancer patients undergoing preoperative Chemoradiotherapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Faramarzi</surname><given-names>Elnaz</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mahdavi</surname><given-names>Reza</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Mohammad-zadeh</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Nasirimotlagh</surname><given-names>Behnam</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sanaie</surname><given-names>Sarvin</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="corresp" rid="cor1"/></contrib></contrib-group><aff id="aff1"><label>1</label>Elnaz Faramarzi, PhD. Assistant Professor of Nutrition, Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff2"><label>2</label>Reza Mahdavi, PhD. Professor of Nutrition, Nutritional Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff3"><label>3</label>Mohammad Mohammad-zadeh, Associate Professor of Radiotherapy, Dept. of Radiotherapy, Shahid Madani Hospital, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff4"><label>4</label>Behnam Nasirimotlagh, Dept. of Radiotherapy, Shahid Madani Hospital, Tabriz University of Medical Sciences, Tabriz, Iran</aff><aff id="aff5"><label>5</label>Sarvin Sanaie, MD, PhD. Assistant Professor of Nutrition, Tuberculosis and Lung disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</aff><author-notes><corresp id="cor1">
Correspondence: Dr. Sarvin Sanaie, MD, PhD. Assistant Professor, Tuberculosis and Lung disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. E-mail: <email xlink:href="sarvin_so2000@yahoo.com">sarvin_so2000@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2017</year></pub-date><volume>33</volume><issue>2</issue><fpage>383</fpage><lpage>388</lpage><history><date date-type="received"><day>16</day><month>11</month><year>2016</year></date><date date-type="rev-recd"><day>03</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>28</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>05</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Pakistan Journal of Medical Sciences</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p><!--CREATIVE COMMONS-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">http://creativecommons.org/licenses/by/3.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title>Objectives:</title><p>This study set out with the aim of evaluating the effect of conjugated linoleic acid (CLA) supplementation on quality of life in rectal cancer patients undergoing to preoperative chemoradiotherapy.</p></sec><sec id="st2"><title>Methods:</title><p>In this study, 33 volunteer patients with rectal cancer treated with preoperative chemoradiotherapy were allocated in the CLA (n=16) and the placebo groups (n=17). The CLA group and placebo groups received 3 gr CLA/d and 4 placebo capsules for 6 weeks respectively. Before and after intervention, quality of life of patients was assessed by EORTC QLQ-C30.</p></sec><sec id="st3"><title>Results:</title><p>At the end of study, the mean scores of physical function, role function, and cognitive function enhanced significantly in the CLA group while reduced remarkably in the placebo group. Symptom scales improved in the CLA group at the end of study. Comparison of changes in fatigue, pain and diarrhea scores were statistically significant between two study groups (P&#x0003c;0.05). When we compared the global health status scores between two groups, significant changes were observed (P&#x0003c;0.001).</p></sec><sec id="st4"><title>Conclusion:</title><p>It appears that CLA may be helpful in rectal cancer patients by improving global quality of life. Although, other clinical trials with large sample size are needed to achieve more precise results.</p></sec></abstract><kwd-group><kwd>Chemoradiotherapy</kwd><kwd>Conjugated linoleic acid</kwd><kwd>Rectal cancer</kwd><kwd>Quality of life</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title>INTRODUCTION</title><p>Colorectal cancer is one of the most common cancers in the world, and it is the third most common cancer in both men and women.<xref rid="ref1" ref-type="bibr">1</xref> The main treatments for rectal cancer include surgery and preoperative chemoradiotherapy (CRT) or postoperative CRT. Multiple anti-cancer treatment increase risk of malnutrition in these patients.<xref rid="ref2" ref-type="bibr">2</xref> The suggested mechanism for inducing of malnutrition by radiotherapy in these patients is that exposure to clinically relevant doses of ionizing radiation can active cytokine cascades which stimulate several biological reactions at the cell and tissue levels. Indeed, it has been reported inflammatory factors (e.g. TNF-&#x003b1;, IL-1&#x003b2;, IL-6, etc) have an important role in metabolic disorders, muscle wasting, and development of symptoms such as anorexia, nausea, fatigue, and pain which affect nutrition status and quality of life of cancer patients.<xref rid="ref3" ref-type="bibr">3</xref></p><p>Thus, it is assumed that new adjuvant anti-inflammatory therapeutic approaches as a complementary therapy may be helpful in preventing of malnutrition and cachexia by down regulate inflammatory signaling pathways.<xref rid="ref4" ref-type="bibr">4</xref> Therefore, preventing of incidence of side effects of cancer treatments by using new adjuvant anti-inflammatory therapeutic approaches can improve nutrition status and quality of life of cancer patients. In this regard, the findings of previous studies have documented that there is significant association between nutrition status and quality of life in cancer patients.<xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref5" ref-type="bibr">5</xref> Taking into account that anti-inflammatory and anticancer effects of conjugated linoleic acid (CLA) has been noted by previous studies.<xref rid="ref6" ref-type="bibr">6</xref>-<xref rid="ref9" ref-type="bibr">9</xref> Conjugated linoleic acids (CLAs) are fatty acids which consist of heterogeneous group of positional and geometric isomers of linoleic acid. Foods originated from ruminant animals (such as dairy products and meats) are the rich source of CLA.<xref rid="ref10" ref-type="bibr">10</xref></p><p>Despite the beneficial effect of CLA on inflammation and malnutrition, as far as we know, no studies have been found that evaluated effect of CLA supplementation on quality of life in cancer patients.</p><p>Considering the importance of supportive care in cancer patients and the important role of inflammation in incidence of symptoms which influence quality of life of cancer patients and anti inflammatory effect of CLA, we examined the effect of CLA supplementation on quality of life in rectal cancer patients treated with preoperative chemoradiotherapy.</p></sec><sec sec-type="methods" id="sec1-2"><title>METHODS</title><p>Thirty-three volunteer patients with rectal cancer were chosen from the radiotherapy center of Imam Hospital in Tabriz. Written informed consent was obtained from all patients. This randomized clinical trial (RCT) was approved by Ethics Committee of Tabriz University of Medical Sciences and registered as the RCT study (IRCT: 201012041197N9).</p><p>Inclusion criteria were rectal cancer patients in stage II or III (based on TNM staging; Tumor-Node-Metastasis), who were candidate to treat neoadjuvant chemoradiotherapy. Treatment protocol is described in details in our previous study.<xref rid="ref8" ref-type="bibr">8</xref> Exclusion criteria were: history of any other cancer, radiotherapy and chemotherapy treatments; underweight (BMI&#x0003c;18.5 kg/m2); vitamin and mineral supplementation within the last month; diabetes; and liver, renal or endocrine dysfunction. The random sequence was performed by computer and the random sequence was kept in a remote secure location. An independent third party who was not involved in the study allocated patients in two groups. Patients and those who were involved in enrolling participants and administering interventions were blind to group assignments. Patients were allocated in the CLA (n=16) and the placebo groups (n=17). CLA group received four 1000 mg capsules (providing 3g CLA) three times/d (1 capsule at breakfast and dinner; two capsules at lunch) and placebo group(n=17) received four placebo capsules for 6 weeks. Placebo capsules contained sunflower oil and their appearance was similar to the CLA capsules. The CLA capsules provided from Tonalin, Natural factor, Canada which included two active isomers 18:2 c9, t11 and 18:2 t10, c12 in a 50/50 ratio. According to the previous study, we decided to use 3 g/d of CLA in this study.<xref rid="ref7" ref-type="bibr">7</xref> For inducing optimal serum levels of CLA, patients receive supplements one week prior to commencing chemoradiotherapy (loading period) and continued everyday up to the end of treatment.</p><p>Patients were checked weekly for any side effects of supplementation. The patients that consumed less than 90% of the planned number of capsules were not included in the analysis. Before and after intervention, quality of life of patients was assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version.3.0 (EORTC QLQ-C30), downloaded from the EORTC website.<xref rid="ref11" ref-type="bibr">11</xref></p><p>The EORTC QLQ-C30 includes Global Health Status\QoL, Functional scales and Symptom scale/ items. Functional scales contain physical, role, emotional, cognitive, and social functioning. In Global health status \QoL and Functional subclasses, high scores indicate a high QoL and a high level of healthy functioning respectively. Symptom scale/ items include fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea and financial difficulties; higher scores show increased severity of symptom.<xref rid="ref12" ref-type="bibr">12</xref>,<xref rid="ref13" ref-type="bibr">13</xref></p><p>EORTC QLQ-C30 is a valid and reliable tool to evaluate quality of life cancer patients. This questionnaire has been translated to different languages. The Persian questionnaire was downloaded from the EORTC website which had been validated previously.<xref rid="ref14" ref-type="bibr">14</xref></p><p>The scoring of different parts of QLQ-C30 was calculated on the guideline of QLQ-C30 scoring. We accessed to this guideline by downloading from the EORTC website (<xref ref-type="table" rid="T1">Table-I</xref>), albeit the permission for using this guideline has been already obtained.</p><table-wrap id="T1" position="float"><label>Table-I</label><caption><p>Scoring the QLQ-C30.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>Number of items</italic></th><th align="center" rowspan="1" colspan="1"><italic>Item range</italic></th><th align="center" rowspan="1" colspan="1"><italic>Item numbers</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Global health status / QoL</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Global health status/QoL</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">29,30</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Functional scales</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Physical functioning</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1 to 5</td></tr><tr><td align="left" rowspan="1" colspan="1">Role functioning</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">6,7</td></tr><tr><td align="left" rowspan="1" colspan="1">Emotional functioning</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">21 to 24</td></tr><tr><td align="left" rowspan="1" colspan="1">Cognitive functioning</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">20,25</td></tr><tr><td align="left" rowspan="1" colspan="1">Social functioning</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">26,27</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Symptom scales / items</bold></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fatigue</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">10,12,18</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea and vomiting</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">14,15</td></tr><tr><td align="left" rowspan="1" colspan="1">Pain</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">9,19</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnoea</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Insomnia</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">Appetite loss</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhoea</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="left" rowspan="1" colspan="1">Financial difficulties</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">28</td></tr></tbody></table></table-wrap><p>The scoring of QLQ-C30 was performed as described below:</p><p>Raw Score = RS= (I<sub>1</sub>+I<sub>2</sub>+&#x02026;+I<sub>n</sub>)/n</p><sec id="sec2-2"><title>Linear transformation</title><p>-Functional scales: S={1-(RS-1)/range)}*100</p><p>-Symptom scale/items: S={(RS-1)/range)}*100</p><p>-Global health status/QL: S={(RS-1)/range)}*100</p></sec><sec id="sec2-3"><title>Statistical Analysis</title><p>The data were analyzed using Statistical Package for the Social Sciences (SPSS, version 11.5, Chicago, IL). The normality of data was assessed by Kolmogorov Smirnov test and the descriptive tests. The independent <italic>t</italic> test, &#x003c7;<sup>2</sup> test, paired-t-test, Signed test, and Mann-Whitney U test were used for data analysis. Effects of confounding factors was adjusted by analysis of covariance test (baseline values of variables). The result of this study is significant at the <italic>P</italic> value of less than 0.05.</p><p>Finally, analysis performed on thirty-one patients (CLA group, n=15; Placebo group, n=16). In the CLA group, one patient consumed less than 90% of the planed number of capsules because of forgetting to take the capsules regularly and in the placebo group, one patient was hospitalized and withdrew from the study.</p></sec></sec><sec sec-type="results" id="sec1-3"><title>RESULTS</title><p>Comparison of baseline characteristics of patients showed no significant differences between two groups (<xref ref-type="table" rid="T2">Table-II</xref>). The mean scores of physical function, role function, and cognitive function changed insignificantly in the CLA group while reduced remarkably in the placebo group are shown in <xref ref-type="table" rid="T3">Table-III</xref>.</p><table-wrap id="T2" position="float"><label>Table-II</label><caption><p>Baseline characteristics of study groups.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>CLA group(n=15)</italic></th><th align="center" rowspan="1" colspan="1"><italic>Placebo group(n=16)</italic></th><th align="center" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t2f1">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="center" rowspan="1" colspan="1">62.4&#x000b1;15.6</td><td align="center" rowspan="1" colspan="1">58.05&#x000b1;16.4</td><td align="center" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender n(%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">8(53.3.8%)</td><td align="center" rowspan="1" colspan="1">10(62.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">7(46.7%)</td><td align="center" rowspan="1" colspan="1">6(37.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage rectal cancer n(%)<xref ref-type="table-fn" rid="t2f2">**</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">6(40%)</td><td align="center" rowspan="1" colspan="1">5 (31.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">9(60%)</td><td align="center" rowspan="1" colspan="1">11 (68.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BMI(kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">25.35&#x000b1;4.26</td><td align="center" rowspan="1" colspan="1">24.85&#x000b1;3.39</td><td align="center" rowspan="1" colspan="1">0.72</td></tr></tbody></table><table-wrap-foot><fn><p>BMI=Body mass index,</p></fn><fn id="t2f1"><label>*</label><p>independent-t-test;</p></fn><fn id="t2f2"><label>**</label><p>based on TNM staging,&#x000b6; &#x003c7;<sup>2</sup>test</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table-III</label><caption><p>Comparison of scores for selected functional and symptom scales before and after intervention in CLA and placebo groups.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1"><italic>CLA group (n=15)</italic></th><th align="center" colspan="4" rowspan="1"><italic>Placebo group (n=16)</italic></th></tr><tr><th align="center" colspan="9" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><italic>Before</italic></th><th align="left" rowspan="1" colspan="1"><italic>After</italic></th><th align="left" rowspan="1" colspan="1"><italic>p</italic></th><th align="left" rowspan="1" colspan="1"><italic>Change</italic></th><th align="left" rowspan="1" colspan="1"><italic>Before</italic></th><th align="left" rowspan="1" colspan="1"><italic>After</italic></th><th align="left" rowspan="1" colspan="1"><italic>p</italic></th><th align="left" rowspan="1" colspan="1"><italic>Change</italic></th></tr></thead><tbody><tr><td align="left" colspan="9" rowspan="1"><italic><bold>Functional Scales</bold></italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Physical function</td><td align="left" rowspan="1" colspan="1">80.51&#x000b1;24.56</td><td align="left" rowspan="1" colspan="1">85.12&#x000b1;20.21</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.58</td><td align="left" rowspan="1" colspan="1">4.61(-13.2-22.43)</td><td align="left" rowspan="1" colspan="1">77.22&#x000b1;28.20</td><td align="left" rowspan="1" colspan="1">63.88&#x000b1;38.39</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.13</td><td align="left" rowspan="1" colspan="1">13.33(-33.44-6.77)</td></tr><tr><td align="left" rowspan="1" colspan="1">Role function</td><td align="left" rowspan="1" colspan="1">88.46&#x000b1;18.49</td><td align="left" rowspan="1" colspan="1">89.74&#x000b1;21.01</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f2">**</xref>0.81</td><td align="left" rowspan="1" colspan="1">1.28(-10.67-13.24)</td><td align="left" rowspan="1" colspan="1">83.33&#x000b1;23.57</td><td align="left" rowspan="1" colspan="1">70.83&#x000b1;40.27</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.3</td><td align="left" rowspan="1" colspan="1">-12.5(-38.09-13.09)</td></tr><tr><td align="left" rowspan="1" colspan="1">Emotional function</td><td align="left" rowspan="1" colspan="1">63.49&#x000b1;37.96</td><td align="left" rowspan="1" colspan="1">24.35&#x000b1;29.94</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f2">**</xref>0.02</td><td align="left" rowspan="1" colspan="1">-39.1(-76.58- -1.62)</td><td align="left" rowspan="1" colspan="1">91.66&#x000b1;12.81</td><td align="left" rowspan="1" colspan="1">27.08&#x000b1;28</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>&#x0003c;0.001</td><td align="left" rowspan="1" colspan="1">-64.58(-85.65&#x02014;43.50)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cognitive function</td><td align="left" rowspan="1" colspan="1">90.21&#x000b1;18.06</td><td align="left" rowspan="1" colspan="1">98.71&#x000b1;4.6</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f2">**</xref>0.16</td><td align="left" rowspan="1" colspan="1">7.69(-3.65-19.03)</td><td align="left" rowspan="1" colspan="1">91.02&#x000b1;17.5</td><td align="left" rowspan="1" colspan="1">90.27&#x000b1;18.66</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f2">**</xref>0.08</td><td align="left" rowspan="1" colspan="1">-9.72(-21.19-1.75)</td></tr><tr><td align="left" colspan="9" rowspan="1"><italic><bold>Symptom scales/item</bold></italic></td></tr><tr><td align="left" rowspan="1" colspan="1">Fatigue</td><td align="left" rowspan="1" colspan="1">16.23&#x000b1;19.57</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f3">&#x000b6;</xref>7.6&#x000b1;17.20</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.11</td><td align="left" rowspan="1" colspan="1">-8.54(-23.59-6.50)</td><td align="left" rowspan="1" colspan="1">16.60&#x000b1;27</td><td align="left" rowspan="1" colspan="1">39.81&#x000b1;38.33</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.02</td><td align="left" rowspan="1" colspan="1">23.14(1.97-44.31)</td></tr><tr><td align="left" rowspan="1" colspan="1">Nausea and vomiting</td><td align="left" rowspan="1" colspan="1">5.12&#x000b1;14.24</td><td align="left" rowspan="1" colspan="1">3.84&#x000b1;9.98</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.85</td><td align="left" rowspan="1" colspan="1">-1.28(-12.5-9.94)</td><td align="left" rowspan="1" colspan="1">5.5&#x000b1;14.79</td><td align="left" rowspan="1" colspan="1">13.88&#x000b1;28.21</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.46</td><td align="left" rowspan="1" colspan="1">8.33(-11.6&#x02014;28.27)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pain</td><td align="left" rowspan="1" colspan="1">30.76&#x000b1;25.31</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f3">&#x000b6;</xref>12.82&#x000b1;21.68</td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">-17.94(-37.43-1.52)</td><td align="left" rowspan="1" colspan="1">23.61&#x000b1;31.34</td><td align="left" rowspan="1" colspan="1">51.38&#x000b1;36.55</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.01</td><td align="left" rowspan="1" colspan="1">27.77(6.92-48.63)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyspnea</td><td align="left" rowspan="1" colspan="1">10.25&#x000b1;21.01</td><td align="left" rowspan="1" colspan="1">7.69&#x000b1;19.95</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.56</td><td align="left" rowspan="1" colspan="1">-2.56(-12.5-7.37)</td><td align="left" rowspan="1" colspan="1">2.77&#x000b1;9.62</td><td align="left" rowspan="1" colspan="1">8.33&#x000b1;20.71</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.31</td><td align="left" rowspan="1" colspan="1">5.55(-6.67-17.78)</td></tr><tr><td align="left" rowspan="1" colspan="1">Insomnia</td><td align="left" rowspan="1" colspan="1">20.51&#x000b1;32.02</td><td align="left" rowspan="1" colspan="1">17.94&#x000b1;29.23</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.59</td><td align="left" rowspan="1" colspan="1">-2.56(23.46-18.33)</td><td align="left" rowspan="1" colspan="1">11.11&#x000b1;21.71</td><td align="left" rowspan="1" colspan="1">36.11&#x000b1;43.71</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.08</td><td align="left" rowspan="1" colspan="1">25(-3.73-53.74)</td></tr><tr><td align="left" rowspan="1" colspan="1">Appetite loss</td><td align="left" rowspan="1" colspan="1">10.25&#x000b1;21.01</td><td align="left" rowspan="1" colspan="1">10.25&#x000b1;21.01</td><td align="left" rowspan="1" colspan="1">-</td><td align="left" rowspan="1" colspan="1">-(-16.44-16.44)</td><td align="left" rowspan="1" colspan="1">19.44&#x000b1;38.81</td><td align="left" rowspan="1" colspan="1">27.77&#x000b1;31.24</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.67</td><td align="left" rowspan="1" colspan="1">8.33(-25.6-42.27)</td></tr><tr><td align="left" rowspan="1" colspan="1">Constipation</td><td align="left" rowspan="1" colspan="1">15.38&#x000b1;29.23</td><td align="left" rowspan="1" colspan="1">2.56&#x000b1;9.24</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.13</td><td align="left" rowspan="1" colspan="1">-12.82(-32.17-6.53)</td><td align="left" rowspan="1" colspan="1">19.44&#x000b1;30.01</td><td align="left" rowspan="1" colspan="1">8.33&#x000b1;20.71</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.19</td><td align="left" rowspan="1" colspan="1">-11.1(-29.91-7.68)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diarrhea</td><td align="left" rowspan="1" colspan="1">25.6&#x000b1;30.89</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f3">&#x000b6;</xref>7.69&#x000b1;19.97</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.0.6</td><td align="left" rowspan="1" colspan="1">-17.94(-37.43-1.53)</td><td align="left" rowspan="1" colspan="1">16.66&#x000b1;22.47</td><td align="left" rowspan="1" colspan="1">47.22&#x000b1;36.12</td><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t3f1">*</xref>0.01</td><td align="left" rowspan="1" colspan="1">30.55(9.45-51.65)</td></tr></tbody></table><table-wrap-foot><fn><p>CLA, conjugated linoleic acid;a Mean value&#x000b1;standard deviation,</p></fn><fn id="t3f1"><label>*</label><p>P, comparison within group by paired-test;</p></fn><fn id="t3f2"><label>**</label><p>P, comparison within group by signed test,</p></fn><fn id="t3f3"><label>&#x000b6;</label><p>significantly different from the placebo group (P&#x0003c;0.05) by Mann Whitney U test.</p></fn></table-wrap-foot></table-wrap><p>Only significant changes were observed in scores of emotional functioning in both groups as compared with baselines (P&#x0003c;0.05). Symptom scales improved in the CLA group at the end of intervention. Comparison of changes in fatigue, pain and diarrhea scores were statistically significant between two study groups (P&#x0003c;0.05).</p><p>The changes of quality of life scores between study groups are shown in <xref ref-type="table" rid="T4">Table-IV</xref>. After intervention, the mean score of global health status increased significantly in the CLA group (P&#x0003c;0.001) and reduced in the placebo group (P=0.02) as compared with the beginning of the study. When we compared the global health status scores between two groups, significant changes were observed (P&#x0003c;0.001). CLA supplementation significantly increased functional scales scores.</p><table-wrap id="T4" position="float"><label>Table-IV</label><caption><p>Comparison of global health status, functional scales and symptom scales before and after intervention in CLA and placebo groups.</p></caption><table frame="hsides" rules="groups" width="100%"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><italic>CLA group (n=15)</italic></th><th align="center" rowspan="1" colspan="1"><italic>Placebo group (n=16)</italic></th><th align="center" rowspan="1" colspan="1"><italic>P</italic><xref ref-type="table-fn" rid="t4f1">*</xref></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic><bold>Global Health status</bold></italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">70&#x000b1;14.363</td><td align="center" rowspan="1" colspan="1">73.71&#x000b1;19.19</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">83.33&#x000b1;10.91</td><td align="center" rowspan="1" colspan="1">55.12&#x000b1;32.90</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t4f2">**</xref>P(Before-After)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t4f4">&#x000b6;</xref>Change</td><td align="center" rowspan="1" colspan="1">12.22(5.51-20.12)</td><td align="center" rowspan="1" colspan="1">-17.36(-0.39- -34.32)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic><bold>Functional Scales</bold></italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">76.75&#x000b1;17.27</td><td align="center" rowspan="1" colspan="1">83.33&#x000b1;17.17</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">86.15&#x000b1;12.99</td><td align="center" rowspan="1" colspan="1">72.22&#x000b1;28.24</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t4f2">**</xref>P(Before-After)</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">0.17</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Change<xref ref-type="table-fn" rid="t4f4">&#x000b6;</xref></td><td align="center" rowspan="1" colspan="1">9.40(-2.51-21.31)</td><td align="center" rowspan="1" colspan="1">-11.11(-27.97-5.75)</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic><bold>Symptom, Scales</bold></italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t4f5">&#x000a7;</xref>Before</td><td align="center" rowspan="1" colspan="1">14.52&#x000b1;11.24</td><td align="center" rowspan="1" colspan="1">14.50&#x000b1;17.71</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t4f5">&#x000a7;</xref>After</td><td align="center" rowspan="1" colspan="1">7.69&#x000b1;11.62</td><td align="center" rowspan="1" colspan="1">30.96&#x000b1;20.57</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t4f3">&#x000a7;&#x000a7;</xref>P(Before-After)</td><td align="center" rowspan="1" colspan="1">0.14</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><xref ref-type="table-fn" rid="t4f4">&#x000b6;</xref> Change</td><td align="center" rowspan="1" colspan="1">-7.49(-17.26-2.27)</td><td align="center" rowspan="1" colspan="1">15.90(3.29-28.52)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr></tbody></table><table-wrap-foot><fn><p>CLA, conjugated linoleic acid, change (differences of baseline and after intervention),</p></fn><fn id="t4f1"><label>*</label><p>P, comparison between group by independent t-test;</p></fn><fn id="t4f2"><label>**</label><p>P comparison within group by paired t &#x02013;test;</p></fn><fn id="t4f3"><label>&#x000a7;&#x000a7;</label><p>P comparison within group by Sign test, ANCOVA was used to adjust baseline values of variables;</p></fn><fn id="t4f4"><label>&#x000b6;</label><p>mean value (95% confidence interval);</p></fn><fn id="t4f5"><label>&#x000a7;</label><p>Mean value&#x000b1;standard deviation.</p></fn></table-wrap-foot></table-wrap><p>After intervention, no significant changes in symptom scale scores found in the CLA group. Although, comparison of symptom scales between two groups revealed that there is a significant (P=0.001) difference (-7.49 vs 15.90).</p></sec><sec sec-type="discussion" id="sec1-4"><title>DISCUSSION</title><p>Nowadays, quality of life of cancer patients become one of the important issues in cancer patients&#x02019; treatment protocol. Several factors such as stage of disease, side effects of anti cancer treatments, depression and inflammation due to cancer or cancer treatments influence quality of life cancer patients. The results of previous studies indicated quality of cancer patients decreased significantly during chemotherapy/radiotherapy.<xref rid="ref15" ref-type="bibr">15</xref>-<xref rid="ref17" ref-type="bibr">17</xref></p><p>In reviewing the literature, no study has been found that evaluated effect of CLA supplementation on quality of life in cancer patients. Thus, the findings of the present study were compared with studies that evaluated the effect of different supplementations (e.g. omega 3 fatty acids) on quality of life in cancer patients.</p><p>Lai et al observed body weight and quality of life scores of cachectic patients with head and neck or gastrointestinal cancer who received celecoxib (COX-2 inhibitors) increased significantly in comparison with the placebo group.<xref rid="ref18" ref-type="bibr">18</xref> Furthermore, other researchers reported that high dense energy and protein supplement contain n-3 fatty acid improved body weight, lean tissue, and quality of life patients with advanced pancreatic cancer.<xref rid="ref19" ref-type="bibr">19</xref></p><p>In another study, Maccio et al found that in patients with advanced gynecological cancer combination of L-carnitine+celecoxib+antioxidants (alpha lipoic acid and carboxycysteine)+Megestrol acetat (MA) was more effective than MA (alone) in improving global quality of life patients.<xref rid="ref20" ref-type="bibr">20</xref> Another results of their study were that inflammatory factors (IL-6, TNF-&#x003b1;, CRP) reduced significantly in the combination treatment group while these variables did not change in the MA group. They concluded that observed improving in quality of life patients were associated with decreasing inflammatory factors.</p><p>Considering the important role of inflammation in occurrence of symptoms due to cancer or cancer treatments, it can be assumed that the improvement of quality of life of patients in the present study may be ascribed to anti-inflammatory properties of CLA. This hypothesis was supported by the results of our previous study that 3gr/d CLA supplementation for 6 weeks in patients with rectal cancer treated with chemoradiothearpy improved inflammatory factors.<xref rid="ref8" ref-type="bibr">8</xref></p><p>After intervention, the average of functional scales scores enhanced in the CLA group and decreased in the placebo group as compared with the beginning of the study. In comparison with the placebo group, CLA significantly increased functional scale scores.</p><p>Functional scales contain physical, role, emotional, cognitive, and social functioning. High scores in functional scales indicate a high level of healthy functioning. It has been reported that nutritional status of patients with cancer influence quality of life.<xref rid="ref3" ref-type="bibr">3</xref> In this regard, Ravasco et al observed dietary counseling in colorectal cancer patients who received radiotherapy had better quality of life function scores corresponding their nutritional status and intake.<xref rid="ref17" ref-type="bibr">17</xref> Findings of another research showed that home parentral nutrition in cancer patients had positive effect on quality of life function scores by correcting or preventing malnutrition.<xref rid="ref21" ref-type="bibr">21</xref> Moreover, it has been reported using nutritional supplements with anti inflammatory effects can improve quality of life of cancer patients by reducing incidence of symptoms of eating problems.<xref rid="ref22" ref-type="bibr">22</xref> In line with this, Mahdavi et al found that CLA supplementation in rectal cancer patients improved nutritional status, symptoms of eating problems and dietary intake. They noted observed positive effects of CLA supplementation in cancer patients can be ascribed to anti-inflammatory effects of CLA.<xref rid="ref9" ref-type="bibr">9</xref> Therefore, positive effect of different nutritional interventions on nutritional status and symptoms of patients can lead to increase physical function, physiologic state and social well being.</p><p>At the end of the study, symptom scale scores increased in the placebo group. These results are consistence with those of another study which reported the mean scores of symptoms (such as diarrhea, fatigue, and appetite loss) significantly increased compared with the pretreatment scores.<xref rid="ref16" ref-type="bibr">16</xref> Also, the findings of another study showed that loss of appetite, nausea/vomiting and diarrhea enhanced significantly in patients with uterine cancer treated with radiotherapy.<xref rid="ref15" ref-type="bibr">15</xref> In comparison with the placebo group, CLA supplementation resulted in significant reduction of scores of symptom scales in the supplemented group. Similar to our results, beta glucan supplementation reduced significantly score of symptom scales in breast cancer undergoing chemotherapy.<xref rid="ref23" ref-type="bibr">23</xref></p><p>Therefore, the observed beneficial effect of CLA supplementation on occurrence of symptoms of eating problems and dietary intake of cancer patients can be attributed to anti-inflammatory effect of CLA which have been reported by some animal studies [24,25] and clinical trials.<xref rid="ref6" ref-type="bibr">6</xref>-<xref rid="ref8" ref-type="bibr">8</xref></p><p>As far as we know this study is the first study which examined the effect of CLA supplementation on quality of life cancer patients. It is the strengths of this study. The limitation of this study is small sample size.</p><p>In conclusion, the results of our research showed that CLA supplementation improved global quality of life, functional scales and decreased score of symptom scales in comparison with the placebo group. It appears that CLA may be helpful in rectal cancer patients by improving global quality of life. Although, other clinical trials with large sample size are needed to achieve more precise results.</p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>The authors are grateful for the financial support of the Nutrition Research Center, Tabriz University of Medical Sciences. The authors are also deeply indebted to all patients who participated in this study.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold><italic>Declaration of conflicting interests:</italic></bold> The authors declared no potential conflicts of interest with respect to the research, authorship, and /or publication of this article.</p></fn></fn-group><sec id="sec1-5"><title/><sec id="sec2-4"><title>Authors&#x02019; Contribution</title><p><bold>EF &#x00026; RM</bold> conceived, designed and did editing of manuscript.</p><p><bold>MM &#x00026; BN</bold> did data collection.</p><p><bold>EF</bold> did statistical analysis.</p><p><bold>EF &#x00026; SS</bold> did manuscript writing.</p><p><bold>SS</bold> did review and final approval of manuscript.</p></sec></sec><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torre</surname><given-names>LA</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Lortet-Tieulent</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Global cancer statistics 2012</article-title><source>Cancer J Clin</source><year>2015</year><volume>65</volume><issue>2</issue><fpage>87</fpage><lpage>108</lpage><comment>doi:10.3322/caac.21262</comment></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van</surname><given-names>Cutsem E</given-names></name><name><surname>Arends</surname><given-names>J</given-names></name></person-group><article-title>The causes and consequences of cancer-associated malnutrition</article-title><source>Euro J Oncol Nurs</source><year>2005</year><volume>9</volume><fpage>S51</fpage><lpage>S63</lpage><comment>doi:10.1016/j.ejon.2005.09.007</comment></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravasco</surname><given-names>P</given-names></name><name><surname>Monteiro-Grillo</surname><given-names>I</given-names></name><name><surname>Vidal</surname><given-names>PM</given-names></name><name><surname>Camilo</surname><given-names>ME</given-names></name></person-group><article-title>Cancer:disease and nutrition are key determinants of patients'quality of life</article-title><source>Support Care Cancer</source><year>2004</year><volume>12</volume><issue>4</issue><fpage>246</fpage><lpage>252</lpage><comment>doi:10.1007/s00520-003-0568-z</comment><pub-id pub-id-type="pmid">14997369</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argiles</surname><given-names>JM</given-names></name><name><surname>Busquets</surname><given-names>S</given-names></name><name><surname>Lopez-Soriano</surname><given-names>FJ</given-names></name></person-group><article-title>Anti-inflammatory therapies in cancer cachexia</article-title><source>Euro J Pharmacol</source><year>2011</year><volume>668</volume><issue>Suppl 1</issue><fpage>S81</fpage><lpage>86</lpage><comment>doi:10.1016/j.ejphar.2011.07.007</comment></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jager-Wittenaar</surname><given-names>H</given-names></name><name><surname>Dijkstra</surname><given-names>PU</given-names></name><name><surname>Vissink</surname><given-names>A</given-names></name><name><surname>van der</surname><given-names>Laan BF</given-names></name><name><surname>van</surname><given-names>Oort RP</given-names></name><name><surname>Roodenburg</surname><given-names>JL</given-names></name></person-group><article-title>Malnutrition and quality of life in patients treated for oral or oropharyngeal cancer</article-title><source>Head Neck</source><year>2011</year><volume>33</volume><issue>4</issue><fpage>490</fpage><lpage>496</lpage><comment>doi:10.1002/hed.21473</comment><pub-id pub-id-type="pmid">20824806</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassaganya-Riera</surname><given-names>J</given-names></name><name><surname>Hontecillas</surname><given-names>R</given-names></name></person-group><article-title>Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2010</year><volume>13</volume><issue>5</issue><fpage>569</fpage><lpage>573</lpage><comment>doi:10.1097/MCO.0b013e32833b648e</comment><pub-id pub-id-type="pmid">20508519</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Grant</surname><given-names>I</given-names></name><name><surname>Rotondo</surname><given-names>D</given-names></name><name><surname>Mohede</surname><given-names>I</given-names></name><name><surname>Sattar</surname><given-names>N</given-names></name><name><surname>Heys</surname><given-names>S</given-names></name><name><surname>Wahle</surname><given-names>K</given-names></name></person-group><article-title>Effect of CLA supplementation on immune function in young healthy volunteers</article-title><source>Euro J Clin Nutr</source><year>2005</year><volume>59</volume><issue>4</issue><fpage>508</fpage><lpage>517</lpage><comment>doi:10.1038/sj.ejcn.1602102</comment></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadzadeh</surname><given-names>M</given-names></name><name><surname>Faramarzi</surname><given-names>E</given-names></name><name><surname>Mahdavi</surname><given-names>R</given-names></name><name><surname>Nasirimotlagh</surname><given-names>B</given-names></name><name><surname>Jafarabadi</surname><given-names>MA</given-names></name></person-group><article-title>Effect of conjugated linoleic Acid supplementation on inflammatory factors and matrix metalloproteinase enzymes in rectal cancer patients undergoing chemoradiotherapy</article-title><source>Integrative Cancer Therapies</source><year>2013</year><volume>12</volume><issue>6</issue><fpage>496</fpage><lpage>502</lpage><comment>doi:10.1177/1534735413485417</comment><pub-id pub-id-type="pmid">23632235</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahdavi</surname><given-names>R</given-names></name><name><surname>Faramarzi</surname><given-names>E</given-names></name><name><surname>Mohammad-Zadeh</surname><given-names>M</given-names></name><name><surname>Nasirimotlagh</surname><given-names>B</given-names></name><name><surname>Ghaemmaghami</surname><given-names>SJ</given-names></name></person-group><article-title>Effects of conjugated linoleic acid supplementation on nutritional status, symptoms of eating problems and dietary intake in rectal cancer patients undergoing chemoradiotherapy</article-title><source>Curr Topics Nutraceutical Res</source><year>2013</year><fpage>11</fpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Storkson</surname><given-names>J</given-names></name><name><surname>Ha</surname><given-names>Y</given-names></name><name><surname>Pariza</surname><given-names>M</given-names></name></person-group><article-title>Dietary sources of conjugated dienoic isomers of linoleic acid, a newly recognized class of anticarcinogens</article-title><source>J Food Composition Analysis</source><year>1992</year><volume>5</volume><issue>3</issue><fpage>185</fpage><lpage>197</lpage><comment>doi:10.1016/0889-1575(92)90037-K</comment></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="book"><collab>EORTC</collab><source>European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)</source><year>2012</year><date-in-citation>Cited 2012 May</date-in-citation><publisher-loc>Brussels, Belgium</publisher-loc><publisher-name>EORTC Quality of life</publisher-name><comment>Available from: <uri xlink:type="simple" xlink:href="http://groups.eortc.be/qol/questionnaires_qlqc30.htm">http://groups.eortc.be/qol/questionnaires_qlqc30.htm</uri></comment></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Cull</surname><given-names>A</given-names></name><name><surname>Duez</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>The European Organization for Research and Treatment of Cancer QLQ-C30:a quality-of-life instrument for use in international clinical trials in oncology</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><issue>5</issue><fpage>365</fpage><lpage>376</lpage><comment>doi:10.1093/jnci/85.5.365</comment><pub-id pub-id-type="pmid">8433390</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fayers</surname><given-names>P</given-names></name><name><surname>Aaronson</surname><given-names>N</given-names></name><name><surname>Bjordal</surname><given-names>K</given-names></name><name><surname>Groenveld</surname><given-names>M</given-names></name><name><surname>Curran</surname><given-names>D</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name></person-group><source>The EORTC QLQ-C30 Scoring Manual Published by:European Organisation for Research and Treatment of Cancer</source><year>2001</year><publisher-loc>Brussels, Belgium</publisher-loc></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safaee</surname><given-names>A</given-names></name><name><surname>Moghim</surname><given-names>Dehkordi B</given-names></name></person-group><article-title>Validation study of a quality of life (QOL) questionnaire for use in Iran</article-title><source>Asian Pacific J Cancer Prevent</source><year>2007</year><volume>8</volume><issue>4</issue><fpage>543</fpage><lpage>546</lpage></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlberg</surname><given-names>K</given-names></name><name><surname>Ekman</surname><given-names>T</given-names></name><name><surname>Gaston-Johansson</surname><given-names>F</given-names></name></person-group><article-title>The experience of fatigue, other symptoms and global quality of life during radiotherapy for uterine cancer</article-title><source>Int J Nurs Stud</source><year>2005</year><volume>42</volume><issue>4</issue><fpage>377</fpage><lpage>386</lpage><comment>doi:10.1016/j.ijnurstu.2004.07.008</comment><pub-id pub-id-type="pmid">15847900</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guren</surname><given-names>MG</given-names></name><name><surname>Dueland</surname><given-names>S</given-names></name><name><surname>Skovlund</surname><given-names>E</given-names></name><name><surname>Fossa</surname><given-names>SD</given-names></name><name><surname>Poulsen</surname><given-names>JP</given-names></name><name><surname>Tveit</surname><given-names>KM</given-names></name></person-group><article-title>Quality of life during radiotherapy for rectal cancer</article-title><source>Euro J Cancer</source><year>2003</year><volume>39</volume><issue>5</issue><fpage>587</fpage><lpage>594</lpage><comment>doi:10.1016/S0959-8049(02)00741-4</comment></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravasco</surname><given-names>P</given-names></name><name><surname>Monteiro-Grillo</surname><given-names>I</given-names></name><name><surname>Vidal</surname><given-names>PM</given-names></name><name><surname>Camilo</surname><given-names>ME</given-names></name></person-group><article-title>Dietary counseling improves patient outcomes:a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>7</issue><fpage>1431</fpage><lpage>1438</lpage><comment>doi:10.1200/JCO.2005.02.054</comment><pub-id pub-id-type="pmid">15684319</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>V</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Richey</surname><given-names>L</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Cannon</surname><given-names>T</given-names></name><name><surname>Shores</surname><given-names>C</given-names></name><etal/></person-group><article-title>Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract</article-title><source>Head Neck</source><year>2008</year><volume>30</volume><issue>1</issue><fpage>67</fpage><lpage>74</lpage><comment>doi:10.1002/hed.20662</comment><pub-id pub-id-type="pmid">17615567</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fearon</surname><given-names>K</given-names></name><name><surname>Von</surname><given-names>Meyenfeldt M</given-names></name><name><surname>Moses</surname><given-names>A</given-names></name><name><surname>Van</surname><given-names>Geenen R</given-names></name><name><surname>Roy</surname><given-names>A</given-names></name><name><surname>Gouma</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia:a randomised double blind trial</article-title><source>Gut</source><year>2003</year><volume>52</volume><issue>10</issue><fpage>1479</fpage><lpage>1486</lpage><comment>doi:10.1136/gut.52.10.1479</comment><pub-id pub-id-type="pmid">12970142</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macci&#x000f2;A</surname><given-names>Madeddu C</given-names></name><name><surname>Gramignano</surname><given-names>G</given-names></name><name><surname>Mulas</surname><given-names>C</given-names></name><name><surname>Floris</surname><given-names>C</given-names></name><name><surname>Sanna</surname><given-names>E</given-names></name><etal/></person-group><article-title>A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers:Evaluating the impact on metabolic and inflammatory profiles and quality of life</article-title><source>Gynecol Oncol</source><year>2012</year><volume>124</volume><issue>3</issue><fpage>417</fpage><lpage>425</lpage><comment>doi:10.1016/j.ygy.no.2011.12.435</comment><pub-id pub-id-type="pmid">22198049</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Culine</surname><given-names>S</given-names></name><name><surname>Chambrier</surname><given-names>C</given-names></name><name><surname>Tadmouri</surname><given-names>A</given-names></name><name><surname>Senesse</surname><given-names>P</given-names></name><name><surname>Seys</surname><given-names>P</given-names></name><name><surname>Radji</surname><given-names>A</given-names></name><etal/></person-group><article-title>Home parenteral nutrition improves quality of life and nutritional status in patients with cancer:a French observational multicentre study</article-title><source>Support Care Cancer</source><year>2014</year><volume>22</volume><issue>7</issue><fpage>1867</fpage><lpage>1874</lpage><comment>doi:10.1007/s00520-014-2164-9</comment><pub-id pub-id-type="pmid">24557011</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laviano</surname><given-names>A</given-names></name><name><surname>Seelaender</surname><given-names>M</given-names></name><name><surname>Sanchez-Lara</surname><given-names>K</given-names></name><name><surname>Gioulbasanis</surname><given-names>I</given-names></name><name><surname>Molfino</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>Fanelli F</given-names></name></person-group><article-title>Beyond anorexia-cachexia. Nutrition and modulation of cancer patients' metabolism:supplementary, complementary or alternative anti-neoplastic therapy?</article-title><source>Euro J Pharmacol</source><year>2011</year><volume>668</volume><issue>Suppl 1</issue><fpage>S87</fpage><lpage>90</lpage><comment>doi:10.1016/j.ejphar.2011.06.060</comment></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostadrahimi</surname><given-names>A</given-names></name><name><surname>Esfahani</surname><given-names>A</given-names></name><name><surname>Asghari</surname><given-names>Jafarabadi M</given-names></name><name><surname>Eivazi</surname><given-names>Ziaei J</given-names></name><name><surname>Movassaghpourakbari</surname><given-names>A</given-names></name><name><surname>Farrin</surname><given-names>N</given-names></name></person-group><article-title>Effect of Beta glucan on quality of life in women with breast cancer undergoing chemotherapy:a randomized double-blind placebo-controlled clinical trial</article-title><source>Adv Pharm Bull</source><year>2014</year><volume>4</volume><issue>Suppl 1</issue><fpage>471</fpage><lpage>477</lpage><comment>doi:10.5681/apb.2014.070</comment><pub-id pub-id-type="pmid">25364665</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Cook</surname><given-names>ME</given-names></name></person-group><article-title>Dietary CLA decreased weight loss and extended survival following the onset of kidney failure in NZB/W F1 mice</article-title><source>Lipids</source><year>2003</year><volume>38</volume><issue>1</issue><fpage>21</fpage><lpage>24</lpage><comment>doi:10.1007/s11745-003-1026-8</comment><pub-id pub-id-type="pmid">12669815</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Changhua</surname><given-names>L</given-names></name><name><surname>Jindong</surname><given-names>Y</given-names></name><name><surname>Defa</surname><given-names>L</given-names></name><name><surname>Lidan</surname><given-names>Z</given-names></name><name><surname>Shiyan</surname><given-names>Q</given-names></name><name><surname>Jianjun</surname><given-names>X</given-names></name></person-group><article-title>Conjugated linoleic acid attenuates the production and gene expression of proinflammatory cytokines in weaned pigs challenged with lipopolysaccharide</article-title><source>J Nutr</source><year>2005</year><volume>135</volume><issue>2</issue><fpage>239</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">15671220</pub-id></element-citation></ref></ref-list></back></article>